Conflict of Interest/Competing Interests: All authors must disclose all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.
If IqNJM receives a manuscript for publication consideration from its Editorial Board members, IqNJM ensures that the entire editorial process is carried out in an unbiased manner and that members who may have a conflict of interest with the manuscript do not take part in any editorial decision of the manuscript. The peer review of such a manuscript is completed by reviewers with no conflict of interest.
Ethical Approval of Studies/Informed Consent: Authors of manuscripts that describe experimental studies on either humans or animals must supply to the Editor a statement that the study was approved by an institutional review committee or ethics committee and that the subjects gave informed consent. Such approval should be described in the Methods section of the manuscript. Additionally, for studies conducted with human subjects, the method by which informed consent was obtained from the participants (i.e., verbal or written) also needs to be stated in the Methods section.
In those situations where a formal institutional review board process is not available, the authors must indicate that the principles outlined in the Declaration of Helsinki have been followed. More information regarding the Declaration of Helsinki can be found at (https://www.wma.net/policy/)
For experiments involving animals, investigators must state the care of the animal and licensing guidelines under which the study was performed and report these in accordance with the ARRIVE (Animals in Research: Reporting In Vivo Experiments) statement and rules of the National Institution of Health (NIH) in the care and use of animal in medical research.
All of these documents will be reviewed by the Join committee of IAMRS & IqNJM for research and publication Ethics.
Registering Clinical Trials: IqNJM requires all articles reporting results of clinical trials to be registered in a public trials registry that is in conformity with the International Committee of Medical Journal Editors (ICMJE). All clinical trials, regardless of when they were completed, and secondary analyses of original clinical trials must be registered before submission of a manuscript based on the trial. Phase I trials designed to study pharmacokinetics or major toxicity are exempt.
Manuscripts reporting on clinical trials (as defined above) should indicate that the trial is registered and include the registry information on a separate page, immediately following the author’s financial disclosure information. Required registry information includes the trial registry name, registration identification number, and the URL for the registry.
Protection of Patients’ Rights to Privacy: Identifying information should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent/guardian, wherever applicable) provides informed consent for publication. Authors should remove patients’ names from figures unless they have obtained informed consent from the patients. The journal abides by the ICMJE guidelines:
- Authors, and not the Journal or its Publisher, need to obtain the patient consent form before submitting their work for publication consideration to IqNJM. Authors should ensure that this patient consent form(s) is properly archived. The consent forms are not to be uploaded with the cover letter or sent through email to the Editorial or Publisher offices.
- If the manuscript contains patient images that preclude anonymity or a description that has an obvious indication of the identity of the patient, a statement about obtaining informed patient consent should be indicated in the manuscript.
The policy of Allegation of misconduct: For duplicate publication, fabricated data, undisclosed conflict of interest, plagiarism and/or other issues of publication and scientific misconduct, IqNJM follows the guidance produced by Committee on Publication Ethics (COPE), World Association of Medical Editors (WAME) and International Committee of Medical Journal Editors (ICMJE). Misconduct can be raised against authors, reviewers, editors, and others.
IqNJM endeavor’s to avoid all possible misconduct. All manuscripts are checked for plagiarism using PlagScan . If the Editor or a reviewer is concerned that some aspect of a submitted article may constitute misconduct in research, publication, or professional behavior, the Journal communicates the same to the author(s) and seeks clarification. However, if the concerns are not satisfactorily resolved by discussion with the author(s), the Journal may report the same to appropriate authorities such as their institutions and, for duplicate publication, the journal in which the previous publication had appeared.
The Journal also encourages its readers to report any published article in which they suspect misconduct through e-mail or letter. Anonymity of the complainant would always be maintained.
Copyrights: In respect to the Iraqi Copyright Protection Law No. (3) of 1971 we are declaring our copyrights policy
As soon as an article is accepted for publication, authors will be requested to assign copyright of the article or manuscript to the journal and publisher. This will ensure the widest possible protection and dissemination of information under copyright laws. Also the Authors should notice that the journal is publishing their contents on the web as an open-access journal and making numbers of printed copies for their personal non-commercial use according to the creative commons attribution – non-commercial 4.0 International (CCBY-NC) license.
More information about the Iraqi copy right law can be find in the link below http://iraqld.hjc.iq:8080/LoadLawBook.aspx?SC=031220056443402
While the advice and information in this journal is believed to be true and accurate at the date of publication, neither the authors, the editor nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty with respect to the material contained herein. The entire contents of the Iraqi National Journal of Medicine are protected under Iraqi and international copyrights. However, the Journal grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy use distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights.
Policies of Complain and Appeals: This procedure applies to complaints about the publishing policies, procedures, and/or actions of the Iraqi National Journal of Medicine editorial staff. This complaint must relate to content or a procedure that was the responsibility of the IqNJM or its Editor.
How to register a complaint
Complaints can be registered by phone, e-mail, or letter to the address provided in the Contacts section. The Journal prefers communication through e-mail because it provides a reliable trail. All complaints are acknowledged at the earliest. The complaint would be followed-up in an unbiased manner and be handled by the person to whom they are made, if possible. The Journal aims to resolve any complaint raised within 2–4 weeks; however, if that is not possible, an interim response would be provided until the complaint is resolved.
If a complainant remains unsatisfied with the final decision of the Editor, the complainant may complain to an external body such as Committee on Publication Ethics, when that body has relevant oversight.
Policies of post-publication Discussions and corrections: Corrections are needed for errors of fact. Matters of the debate are best handled as letters to the editor, like print or electronic correspondence. Updates of previous publications (e.g., an updated systematic review or clinical guideline) are considered a new publication rather than a version of a previously published article.
If a correction is needed, journals are following these standards: The journal will publish a correction notice as soon as possible detailing changes from and citing the original publication; the correction should be on an electronic or numbered print page that is included in an electronic or a print Table of Contents to ensure proper indexing.
- The journal also will post a new article version with details of the changes from the original version and the date(s) on which the changes were made.
- The journal will archive all prior versions of the article. This archive can be either directly accessible to readers or can be made available to the reader on request.
- Previous electronic versions will prominently note that there are more recent versions of the article.
- The citation will be the most recent version.
Data and reproducibility: Journals should include policies on data availability and encourage the use of reporting guidelines and registration of clinical trials and other study designs according to standard practice in their discipline.
Policies for intellectual properties:
Authors should not submit the same manuscript, in the same or different languages, simultaneously to more than one journal. The rationale for this standard is the potential for disagreement when two (or more) journals claim the right to publish a manuscript that has been submitted simultaneously to more than one journal, and the possibility that two or more journals will unknowingly and unnecessarily undertake the work of peer review, edit the same manuscript, and publish the same article.
Duplicate and Prior Publication
Duplicate publication is a publication of a paper that overlaps substantially with one already published, without clear, visible reference to the previous publication. Prior publication may include the release of information in the public domain. In the event of a public health emergency (as defined by public health officials), information with immediate implications for public health should be disseminated without concern that this will preclude subsequent consideration for publication in a journal. We encourage editors to give priority to authors who have made crucial data publicly available (e.g., in a gene bank) without delay. The ICMJE will not consider as prior publication the posting of trial results in any registry that meets the criteria noted in Section III.L. If results are limited to a brief (500 words) structured abstract or tables (to include participants enrolled, key outcomes, and adverse events). The ICMJE encourages authors to include a statement with the registration that indicates that the results have not yet been published in a peer-reviewed journal, and to update the results registry with the full journal citation when the results are published.
Authors who attempt duplicate publication without such notification should expect at least prompt rejection of the submitted manuscript. If the editor was not aware of the violations and the article has already been published, then the article might warrant retraction with or without the author’s explanation or approval.
Acceptable Secondary Publication
Secondary publication of material published in other journals or online may be justifiable and beneficial, especially when intended to disseminate important information to the widest possible audience (e.g., guidelines produced by government agencies and professional organizations in the same or a different language). Secondary publication for various other reasons may also be justifiable provided the following conditions are met:
- 1. The authors have received approval from the editors of both journals (the editor concerned with secondary publication must have access to the primary version).
- 2. The priority of the primary publication is respected by a publication interval negotiated by both editors with the authors.
- 3. The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
- 4. The secondary version faithfully reflects the authors, data, and interpretations of the primary version.
- The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere—for example, with a note that might read, “This article is based on a study first reported in the [journal title, with full reference]”—and the secondary version cites the primary reference.
- The title of the secondary publication should indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the NLM does not consider translations to be “republications” and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.